Related Experiment Video
Updated: Apr 21, 2026
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
10.3K
[The genome and pharmacology]
1Institut for Sundhedstjenesteforkning, Klinisk Farmakologi, Syddansk Universitet, J.B. Winsløwsvej 19, 5000 Odense C. kbrosen@health.sdu.dk.
Ugeskrift for Laeger
|November 15, 2014
Summary
Pharmacogenetics studies how genetic mutations impact drug response. Current evidence suggests pre-treatment genetic testing for CYP2C9, VKORC1, CYP2C19, CYP2D6, CYP3A5, SLCOB1, and OCT1 gene variants offers limited practical benefit for warfarin, clopidogrel, tamoxifen, tacrolimus, simvastatin, and metformin therapies.
Area of Science:
- Pharmacogenetics and its role in drug metabolism and response.
- Focus on genetic variations in cytochrome P450 (CYP) enzymes and drug transporters.
Background:
- Germ line mutations significantly influence individual drug responses.
- Single nucleotide polymorphisms (SNPs) in CYP genes are extensively studied.
- Understanding genetic factors is crucial for personalized medicine.
Purpose of the Study:
- To summarize current knowledge on pharmacogenetics for specific drug-gene-polymorphism interactions.
- To evaluate the clinical utility of genotyping for selected drugs and genetic variants.
- To assess the practical application of pharmacogenetic testing in routine clinical practice.
Main Methods:
- Systematic review of existing literature on pharmacogenetics.
- Analysis of studies involving CYP2C9, VKORC1, CYP2C19, CYP2D6, CYP3A5, SLCOB1, and OCT1.
- Evaluation of clinical trial data and observational studies on drug response.
Main Results:
- Genotyping for CYP2C9/VKORC1 and warfarin showed limited practical utility.
- Genotyping for CYP2C19 and clopidogrel provided little clinical benefit.
- Genotyping for CYP2D6 and tamoxifen, and CYP3A5 and tacrolimus, is of limited practical use.
- Polymorphisms in SLCOB1 for simvastatin and OCT1 for metformin also demonstrated minimal clinical utility.
Conclusions:
- Pre-treatment genotyping for the studied drug-gene pairs offers little practical advantage.
- Current pharmacogenetic knowledge does not strongly support routine genotyping for these specific therapies.
- Further research may be needed to identify specific patient subgroups who could benefit from genetic testing.
More Related Videos
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
216
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
216
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
142
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
142
01:29Pharmacogenomics: Identification of New Drug Targets
108
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
108
01:27Principles of Pharmacogenetics: Types of Genetic Variants
122
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
122
01:27Pharmacogenetics of Drug Metabolism: Overview
175
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
175
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
74
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
74